Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated lactobacillus crispatus
- Development stage
- Unknown
- Lead developer
- Shenzhen People's Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
Inactivated *Lactobacillus crispatus* is a non-viable microbial preparation (postbiotic) derived from the Gram-positive bacterium *L. crispatus*. It is currently being investigated by Shenzhen People's Hospital as a topical intervention for obesity-induced skin barrier dysfunction. In clinical research, it is administered as a topical solution to the forearms of obese individuals (BMI ≥25) to evaluate its safety and efficacy, primarily serving as the placebo control in trials comparing it against live *L. crispatus* probiotics. The study investigates whether topical application can restore skin barrier integrity, reduce transepidermal water loss (TEWL), and modulate local inflammatory markers such as interleukin-1 beta (IL-1β) and tumor necrosis factor alpha (TNF-α), as well as the composition of the skin microbiota.
- Other names
- inactivated L. crispatusheat-killed Lactobacillus crispatus
02
Targets
IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on inactivated lactobacillus crispatus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated lactobacillus crispatus.